1187086-96-9

Basic information

• Product Name: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide
• Synonyms: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide
• CAS NO: 1187086-96-9
• Molecular Weight: 289.644
• Mol File: 1187086-96-9.mol

Chemical Properties

• CAS DataBase Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide(1187086-96-9)
• EPA Substance Registry System: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide(1187086-96-9)

Safety Data

• Hazardous Substances Data: 1187086-96-9(Hazardous Substances Data)

Upstream product

• 288-32-4 1H-imidazole 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 284461-73-0 sorafenib 
• 284462-98-2 methyl 3-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy) benzoate 
• 1415661-97-0 3-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-hydroxybenzamide 
• 1130115-44-4 N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl-d₃)aminoformyl)-4-pyridyloxy)phenyl)urea 
• 1547120-45-5 C₂₄H₁₉ClF₃N₅O₂ 
• 1547120-50-2 C₂₄H₁₈ClF₄N₅O₂ 
• 1547120-51-3 C₂₄H₁₈Cl₂F₃N₅O₂ 
• 1547120-56-8 C₂₄H₁₈BrClF₃N₅O₂ 

Relevant articles and documents

Method for synthesizing sorafenib through solid ball milling

The invention relates to a method for synthesizing sorafenib through solid ball milling. The method comprises the following steps: taking a compound 4-(4-aminophenoxy)-N-methylpyridine-2-formamide anda compound 4-chlorine-3-trifluoromethyl isocyanate as raw materials, or taking a compound 4-chlorine-3-trifluoromethyl phenylamine, a compound N,N'-carbonyl diimidazole and a compound 4-(4-aminophenoxy)-N-methylpyridine-2-formamide as raw materials, and performing solid ball milling on the raw materials in a ball mill under the catalysis of a small amount of liquid (and alkali), so as to synthesize the sorafenib. The method has the main innovation points that the sorafenib is firstly synthesized in the ball mill through solid ball milling, and compared with the conventional method of synthesizing sorafenib in a liquid solvent, the method has the advantages of high reaction speed, not overflowed dust, good reaction controllability, high simpleness in operation, high reaction yield, small pollution and high feasibility.

Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase

A series of novel indole derivatives were designed and synthesized and their inhibitory activity against B-Raf and HepG2 cell were also described. Among them, compounds 7a and 7b exhibited excellent potency, which showed the potential for further research

DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS

This invention relates to deuterated ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof. And the pharmaceutical compositions comprising the pharmaceutically acceptable carrier and the deuterium-substituted ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof are also provided. The deuterium-substituted diphenylurea can be used in treatment or prevention of cancer and other related diseases.

Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: Kinetics and application

N-Carbamoylimidazoles dissociate in solution to yield imidazole and an isocyanate that may be reacted with another aryl amine to form an unsymmetrical biaryl urea. This paper investigates the reaction kinetics and the influence of electron withdrawing/donating substituents on the reaction of N-carbamoylimidazoles with aniline. The overall reaction mechanism involves two zwitterionic intermediates, formed during dissociation and upon reaction of the liberated isocyanate with aniline. The rate limiting step for the reaction is a base catalysed proton transfer from the second zwitterionic intermediate. Although electron withdrawing substituents on the aryl group hinder dissociation, they significantly increase reaction rates compared to compounds bearing electron donating substituents. The imidazole liberated upon dissociation catalyses the rate determining step so that reactions of dissociated N-carbamoylimidazoles proceed more rapidly than those involving only isocyanates. In addition, the imidazole eliminates the need for anhydrous reaction conditions. The N-carbamoylimidazole methodology was demonstrated by preparing sorafenib, a biaryl urea kinase inhibitor, in good yield and excellent purity.

Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors

A series of diaryl ether hydroxamic acids were synthesized for the first time and evaluated for the HDAC biology and antiproliferative activity. The structures of these new hydroxamic acids derivatives were confirmed by IR, 1H-NMR and mass spectrum. Some of these compounds showed micro molar activity in the HDAC inhibitory assay and against four cancer cell lines.

Process for the preparation of sorafenib and salts thereof

Methods for the synthesis of the N-carbamoyl imidazole (I) and its 1:1 adduct with imidazole are provided. Methods for the preparation of these crystalline intermediates in a high state of purity are also provided. These intermediates react cleanly under mild conditions to produce sorafenib in high yield and purity, without generating difficult-to-remove impurities.